Taysha Gene Therapies appoints Alison Long to Board; Kathleen Reape resigns

Taysha Gene Therapies, Inc.

Kathleen Reape resigns from Board effective Nov 1, 2023, per employer governance rules; no disagreement with company.
Alison Long appointed as Class I director effective Nov 1, 2023, and chair of Clinical and Science Committee.
Long also appointed to Compensation and Nominating & Corporate Governance Committees.
Long receives initial stock option for 43,800 shares vesting over 36 months plus annual retainers ($35k director, extra committee fees).
Long currently CMO of Flightpath Biosciences (consulting) and Clinical Lead of Enigma Biomedical Group; previously CMO at Anokion, Kaleido.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Alison Long

Director

TSHA · Taysha Gene Therapies, Inc.

Effective: 2023-11-01
Filed: November 1, 2023, 7:59 PM ET

On October 30, 2023, the Board appointed Alison Long to serve as a director of the Company, effective immediately following Dr. Reape’s resignation (the “ Effective Time ”).

Departed

Kathleen Reape

Director

TSHA · Taysha Gene Therapies, Inc.

Effective: 2023-11-01
Successor: Alison Long
Filed: November 1, 2023, 7:59 PM ET

Kathleen Reape provided notice to the board of directors (the “ Board ”) of Taysha Gene Therapies, Inc. (the “C ompany ”) of her decision to resign from the Board and all committees thereof, effective November 1, 2023, in accordance with the governance guidelines of Dr. Reape’s employer and not as a result of any disagreement with the Company.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Alison Long was appointed as Director at Taysha Gene Therapies, Inc..

Action: appointed
Role: Director

Exact text from the filing

On October 30, 2023, the Board appointed Alison Long to serve as a director of the Company, effective immediately following Dr. Reape’s resignation (the “ Effective Time ”).

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 1.0

Kathleen Reape resigned as Director at Taysha Gene Therapies, Inc..

Action: resigned
Role: Director

Exact text from the filing

Kathleen Reape provided notice to the board of directors (the “ Board ”) of Taysha Gene Therapies, Inc. (the “C ompany ”) of her decision to resign from the Board and all committees thereof, effective November 1, 2023, in accordance with the governance guidelines of Dr. Reape’s employer and not as a result of any disagreement with the Company.

View on SEC.gov

Taysha Gene Therapies, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-268173

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.